Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Chx10 CRISPR/Cas9 KO Plasmid (h): sc-401103
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Chx10 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Chx10 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Chx10 Antibody (E-12): sc-365519
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Chx10 CRISPR/Cas9 KO Plasmid (h) | sc-401103 | 20 µg | $397.00 |
Overview
VSX2 (Chx10) is a homeobox transcription factor that plays a central role in eye field specification and retinal progenitor cell proliferation, helping coordinate neurogenesis and cell fate decisions during vertebrate retinogenesis. It regulates transcriptional programs controlling retinal bipolar neuron development and maintenance of neural retinal identity, interfacing with developmental signaling networks such as WNT/β-catenin, SHH, and Notch-associated gene regulation. Altered VSX2 function has been linked to congenital ocular malformations including microphthalmia and anophthalmia, and dysregulated expression is relevant to studies of retinal dystrophy mechanisms and stem cell–derived retinal organoid development. As a DNA-binding regulator, Chx10 is commonly investigated for its effects on differentiation trajectories, lineage commitment, and gene regulatory networks in ocular and neural models.
Chx10 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the VSX2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the VSX2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the VSX2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Chx10 protein expression.
This CRISPR knockout system enables efficient generation of VSX2-deficient cell models for investigation of Chx10 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting VSX2 exon(s) critical for Chx10 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple VSX2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Chx10 CRISPR/Cas9 KO Plasmid (h) and Chx10 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the VSX2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Chx10 HDR Plasmid (h) and Chx10 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by VSX2 homology arms to support homology-directed repair at defined VSX2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.